Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HERB trial of trastuzumab deruxtecan in HER2-positive unresectable or recurrent biliary tract cancer
jRCT2091220423Completed
- Sponsor
- National Cancer Center Hospital
- Start
- May 2019
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of trastuzumab deruxtecan in biliary cancer, sponsored by National Cancer Center Hospital. Primary endpoint: Overall response rate in HER2-positive population. Started May 2019; status: completed.
02
Drugs
trastuzumab deruxtecan
03
Conditions
biliary cancer
Beyond the preview
Go deeper on jRCT2091220423.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2091220423.